Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017; 71: 462-75

被引：2

作者：

Bokarica, Pero ^{[1
]}

Hrkac, Adelina ^{[1
]}

Gilja, Ivan ^{[1
]}

机构：

[1] Clin Hosp Sveti Duh, Dept Urol, Sveti Duh 64, Zagreb 10000, Croatia

来源：

EUROPEAN UROLOGY | 2017年 / 72卷 / 02期

关键词：

D O I：

10.1016/j.eururo.2017.02.031

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E45 / E45

页数：1

共 44 条

[21] Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017; 71: 1-3
Cronauer, Marcus V.
Merseburger, Axel S.
Hoda, M. Raschid
EUROPEAN UROLOGY, 2017, 71 (04) : E105 - E106
[22] Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017; 71: 1-3
Steinestel, Julie
Bernemann, Christof
Schrader, Andres J.
Lennerz, Jochen K.
EUROPEAN UROLOGY, 2017, 71 (04) : E107 - E108
[23] Re: Per-Uno Malmstrom, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247-56
Aldemir, Mustafa
Canda, Abdullah Erdem
Balbay, Mevlana Derya
EUROPEAN UROLOGY, 2010, 58 (02) : E23 - E23
[24] Re: Per-Uno Malmstrom, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247-56
Lamm, Donald
Boehle, Andreas
Palou, Joan
Persad, Raj
Brausi, Maurizio
Colombel, Marc
Akaza, Hideyuki
Buckley, Roger
EUROPEAN UROLOGY, 2010, 57 (02) : E7 - E9
[25] Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016; 70: 1052-68 Preoperative Bladder Cancer History and Chronic Kidney Disease Are Associated with Occult Renal Pelvis Cancer in Preoperative Solitary Ureteral Cancer
Luo, Hao Lun
Chen, Yen Ta
Cheng, Yuan Tso
Chiang, Po Hui
EUROPEAN UROLOGY, 2017, 71 (04) : E109 - E110
[26] Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534
Tan, Wei Shen
O'Donnell, Michael
Li, Roger
Kamat, Ashish M.
Packiam, Vignesh T.
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (01): : 164 - 165
[27] Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjodahl, Gottfrid
Abrahamsson, Johan
Holmsten, Karin
Bernardo, Carina
Eriksson, Pontus
Kollberg, Petter
Marzouka, Nour-al-Dain
Hoglund, Mattias
Ullen, Anders
Liedberg, Fredrik
EUROPEAN UROLOGY, 2022, 81 (04) : E92 - E93
[28] Re: Bas WG van Rhijn, Anouk E. Hentschel, Johannes Brundl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91
Cimadamore, Alessia
Lopez-Beltran, Antonio
Scarpelli, Marina
Cheng, Liang
Montironi, Rodolfo
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04): : 671 - 673
[29] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Garg, Harshit
Nayak, Brusabhanu
Singh, Prabhjot
EUROPEAN UROLOGY, 2019, 75 (02) : E25 - E25
[30] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Poletajew, Slawomir
Radziszewski, Piotr
Palou, Juan
EUROPEAN UROLOGY, 2017, 71 (01) : E29 - E30

← 1 2 3 4 5 →